Marksans Pharma Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MARKSANS.BO | MRK | KOPRAN.BO | SOLARA.NS | STAR.BO | IOLCP.NS | |
|---|---|---|---|---|---|---|
| Market cap | 142.25B | 370.96B | 12.80B | 31.04B | 92.73B | 55.50B |
| P/E (TTM) | 40.4 | 151.9 | 51.2 | 83.4 | 15.0 | 27.3 |
| Forward P/E | 30.4 | 16.7 | 39.7 | 20.5 | 11.7 | 17.5 |
| Price/book | 5.3 | 8.9 | 2.4 | 2.2 | 2.7 | 2.9 |
| Dividend yield | 0.45% | 2.26% | 1.25% | — | 0.49% | 0.54% |
| 1-year change | −34.32% | +75.29% | +56.40% | +14.61% | +5.44% | +102.86% |
| Today | +4.15% | +3.93% | +5.79% | −0.25% | −0.58% | +2.89% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All MARKSANS.BO news ›Marksans Pharma Q2 Profit Soars 45% To ₹143.5 Crore, Revenue Crosses ₹900 Crore For First Time As Global Business Shines
Mumbai: Marksans Pharma reported strong financial results for the second quarter of FY27, with net profit rising 44.8 per cent year-on-year to Rs 143.5 crore, compared with Rs 99.1 crore in the same quarter last year. The pharmaceutical…
Marksans Pharma Limited to report Q2 FY27 results November 4
Marksans Pharma Limited is scheduled to consider and approve its unaudited standalone and consolidated Q2 FY27 results on November 4, 2026, following Q1 revenue reported as 840 and year-on-year growth of 35.62%. The board meeting will also…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- freepressjournal.in1
- multibagg.ai1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.